-
公开(公告)号：US11485790B2
公开(公告)日：2022-11-01
申请号：US15302439
申请日：2015-04-07
发明人： Tomoyuki Igawa , Taro Miyazaki , Kenji Taniguchi , Naoka Hironiwa
IPC分类号： C07K16/28 , C07K16/30 , A61K39/395 , C07K16/46 , A61K39/00
摘要： It was discovered that the use of an antigen-binding molecule having a cancer-specific antigen-binding domain, and a TNF superfamily-binding domain or a TNF receptor superfamily-binding domain enables agonist activity against a factor belonging to the TNF superfamily or the TNF receptor superfamily to be exhibited only in the presence of cancer-specific antigen-expressing cells, thus leading to activation of immune cells and thereby maintain anti-tumor activity while avoiding side effects such as hepatotoxicity. It was also discovered that concomitant use of the antigen-binding molecule with an antigen-binding molecule having a cancer-specific antigen-binding domain and a T cell receptor complex-binding domain can avoid side effects while increasing the anti-tumor activity.
-
2.发明申请公开(公告)号：US20200377595A1
公开(公告)日：2020-12-03
申请号：US16769299
申请日：2018-12-04
发明人： Shun Shimizu , Shu Wen Samantha Ho , Naoka Hironiwa , Mika Sakurai , Taro Miyazaki , Tomoyuki Igawa
摘要： Antigen-binding domains that are capable of binding to CD3 and CD137 but do not bind to CD3 and CD137 at the same time and methods of using the same are provided. Methods to obtain antigen binding domains which bind to two or more different antigen more efficiently are also provided.
-
公开(公告)号：US20170145111A1
公开(公告)日：2017-05-25
申请号：US15402580
申请日：2017-01-10
CPC分类号： C07K16/36 , C07K16/40 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/56 , C07K2317/622 , C07K2317/75
摘要： The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX/F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44/B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII.
-
公开(公告)号：US20240190997A1
公开(公告)日：2024-06-13
申请号：US18586698
申请日：2024-02-26
CPC分类号： C07K16/36 , C07K16/00 , C07K16/40 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/56 , C07K2317/622 , C07K2317/75
摘要： The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX/F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44/B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII.
-
公开(公告)号：US11660340B2
公开(公告)日：2023-05-30
申请号：US15776587
申请日：2016-11-17
IPC分类号： A61P35/00 , A61K39/395 , A61K45/00 , A61K31/7068 , A61K33/243 , A61K39/00
CPC分类号： A61K39/39558 , A61K31/7068 , A61K33/243 , A61K39/395 , A61K45/00 , A61P35/00 , A61K2039/505 , A61K2039/507
摘要： The present invention provides methods for treating or preventing cancer by administering an anticancer agent and an antigen-binding molecule comprising a domain that binds to a molecule expressed on the surface of a cell having an immune response-suppressing function and a T cell receptor complex-binding domain. The present invention also provides pharmaceutical compositions for treating or preventing cancer, each comprising a combination of the anticancer agent and the antigen-binding molecule.
-
公开(公告)号：US20200277402A1
公开(公告)日：2020-09-03
申请号：US16825513
申请日：2020-03-20
摘要： The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX/F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44/B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII.
-
公开(公告)号：US20180244800A1
公开(公告)日：2018-08-30
申请号：US15963345
申请日：2018-04-26
CPC分类号： C07K16/36 , C07K16/40 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/56 , C07K2317/622 , C07K2317/75
摘要： The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX/F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44/B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII.
-
8.发明授权公开(公告)号：US11952422B2
公开(公告)日：2024-04-09
申请号：US16769299
申请日：2018-12-04
发明人： Shun Shimizu , Shu Wen Samantha Ho , Naoka Hironiwa , Mika Sakurai , Taro Miyazaki , Tomoyuki Igawa
CPC分类号： C07K16/2809 , C07K16/2863 , C07K16/2878 , C07K16/303 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/526 , C07K2317/55 , C07K2317/56 , C07K2317/622 , C07K2317/71 , C07K2317/75 , C07K2317/92 , C40B30/04
摘要： Antigen-binding domains that are capable of binding to CD3 and CD137 but do not bind to CD3 and CD137 at the same time and methods of using the same are provided. Methods to obtain antigen binding domains which bind to two or more different antigen more efficiently are also provided.
-
公开(公告)号：US20210380717A1
公开(公告)日：2021-12-09
申请号：US17389534
申请日：2021-07-30
摘要： The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX/F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44/B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII.
-
公开(公告)号：US20210107995A1
公开(公告)日：2021-04-15
申请号：US17130736
申请日：2020-12-22
摘要： The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX/F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44/B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII.
-
-
-
-
-
-
-
-
-
搜索结果
16 条记录 (耗时 0.021 秒)
